Name: How soon will new “immune therapies” become mainstream?
Uploaded: 2017-07-27T08:35:01-0700
Duration: 5 min 44 s
Description: In this week’s video, Dr. Brian G.M. Durie discusses the pros and cons of newer “immune therapies,” including monoclonal antibodies, checkpoint inhibitors, bispecific antibodies, and CAR-T cells.

In this week’s video, Dr. Brian G.M. Durie discusses the pros and cons of newer “immune therapies,” including monoclonal antibodies, checkpoint inhibitors, bispecific antibodies, and CAR-T cells.

BOTTOM LINE:
Immune therapies are here to stay, and many will be impactful in the next few years.

If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected].

To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected].

Image of Dr. Brian G.M. Durie Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.